Adverum Biotechnologies Return on Equity

Adverum Biotechnologies (ADVM) currently reports a ROE of 3.18%. That is above the Healthcare sector average of 29.39%. Use the charts on this page to explore Adverum Biotechnologies's ROE history and peer comparisons.

Adverum Biotechnologies's ROE of 3.18% is higher than the Healthcare sector average of 29.39%. That is roughly 980.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Adverum Biotechnologies's current 3.18% should be judged against Healthcare norms (sector average: 29.39%) and against ADVM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 3.18%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Adverum Biotechnologies, and consider following ADVM for alerts when major investors trade the stock.

Adverum Biotechnologies is classified in the Healthcare sector. On ROE, it currently shows 3.18% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADVM with unrelated industries.